Pinealon
A Russian "short peptide" bioregulator for neuroprotection and aging — almost entirely preclinical and domestic research.
Verdict — D · Speculative
A short-peptide bioregulator whose claims rest on a narrow, largely-unreplicated Russian research base. No specific safety alarm, but the evidence and sourcing simply are not there — Speculative, high caution.
Overview
Pinealon is a synthetic tripeptide (Glu-Asp-Arg) from the Khavinson school of "peptide bioregulators" in Russia, studied for neuroprotection, cognitive function and aging. Its evidence base is almost entirely Russian preclinical and small human work, with limited independent international replication and a mechanism asserted more than demonstrated in human tissue. There is no major safety signal for such short peptides, but the combination of thin, geographically narrow evidence and unverifiable research-grade sourcing keeps it speculative.
PepScore Breakdown — the four axes
Evidence
35% weightHow strong is the published human science?
Sourcing & COA
30% weightOur moatCan a buyer obtain an independently-verified, high-purity version? — our proprietary layer.
Safety & Risk
25% weightWhat is the real-world harm potential?
Practicality
10% weightHow easy is it to actually run a verified version?
Sources & Citations
Every claim cites a primary source. Citations are machine-audited against NCBI — see methodology.
Want a clinical path?
Talk to a licensed provider about Pinealon and whether it's appropriate for your situation.
Talk to a Provider ↗Telehealth. Not medical advice — for educational purposes.
Get the PepEvolution Dispatch
Monthly COA findings, vendor changes, and new grades. Research/educational only — no spam.
Free. Unsubscribe anytime. Research/educational content only.
Educational only — not medical advice. PepScore is an educational research grade, not a prescription or dosing recommendation. Some vendor links are affiliate links — this never affects grades. Consult a licensed healthcare provider before using any compound.